IRAK4

IRAK4 (interleukin-1 receptor-associated kinase 4) is a cytoplasmic serine/threonine kinase that belongs to the IRAK family. It plays a central role in signaling from Toll-like receptors (TLRs) and the IL-1 receptor, translating extracellular detection of microbes into inflammatory gene expression.

Biochemical function: In resting cells, MyD88 recruits IRAK4 to the receptor-associated complex via its death domain. Activated IRAK4 phosphorylates IRAK1 and itself, promoting recruitment of TRAF6 and downstream signaling components. This leads to activation of TAK1 and the IKK and MAPK cascades, resulting in transcription of proinflammatory cytokines and mediators such as IL-6, TNF, and IL-1β.

Clinical significance: Mutations in IRAK4 cause IRAK4 deficiency, a primary immunodeficiency characterized by recurrent, serious bacterial infections early in life, particularly with encapsulated organisms. IL-1/TLR signaling is impaired, while some antiviral responses may be relatively preserved. Management includes vaccination and prompt antibiotic treatment; long-term antibiotic prophylaxis is used in some cases.

Therapeutic targeting and research: Inhibitors of IRAK4 have been explored as potential therapies for inflammatory diseases driven by IL-1 or TLR signaling. Several compounds have shown activity in preclinical studies and early clinical trials, but none have established approval for routine use. Ongoing research assesses their safety, efficacy, and suitability for specific inflammatory or neoplastic conditions.